Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

BACKGROUND: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chataway, Jeremy, De Angelis, Floriana, Connick, Peter, Parker, Richard A, Plantone, Domenico, Doshi, Anisha, John, Nevin, Stutters, Jonathan, MacManus, David, Prados Carrasco, Ferran, Barkhof, Frederik, Ourselin, Sebastien, Braisher, Marie, Ross, Moira, Cranswick, Gina, Pavitt, Sue H, Giovannoni, Gavin, Gandini Wheeler-Kingshott, Claudia Angela, Hawkins, Clive, Sharrack, Basil, Bastow, Roger, Weir, Christopher J, Stallard, Nigel, Chandran, Siddharthan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029307/
https://www.ncbi.nlm.nih.gov/pubmed/31981516
http://dx.doi.org/10.1016/S1474-4422(19)30485-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029307/
https://www.ncbi.nlm.nih.gov/pubmed/31981516
http://dx.doi.org/10.1016/S1474-4422(19)30485-5

Ejemplares similares